

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



利君國際醫藥(控股)有限公司
Lijun International Pharmaceutical (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

BUSINESS UPDATE

This announcement is made by Lijun International Pharmaceutical (Holding) Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company is pleased to announce that on 21 January 2015, Shijiazhuang No.4 Pharmaceutical Co., Ltd. (“No.4 Pharma”), a wholly owned subsidiary of the Group, has entered into a letter of intent with the current shareholders of Hebei Hanlin Biotechnology Co., Ltd. (“Hebei Hanlin”) with the following terms.

1. No. 4 Pharma intends to inject RMB 20 million to take an equity position in Hebei Hanlin, whose current shareholders shall use the current scientific research projects and relevant achievements as contribution (including but not limited to technologies in antibody preparation and Therapeutic Antibody, HPV test kit etc). Hebei Hanlin’s shareholders guarantee the current projects and relevant achievements do not constitute infringement on any third party. The parties shall arrange for the shareholding restructuring on Hebei Hanlin after which each of No. 4 Pharma and current shareholders of Hebei Hanlin should hold 50% equity shares of Hebei Hanlin.
2. Hebei Hanlin keeps on conducting development works on Antibody, Therapeutic Antibody, HPV test kit, peptide and health products with the current technologies and the products bases and by tracing the PRC and overseas advanced biotechnologies after shareholding restructuring.
3. The parties agree to enter into a formal agreement and complete Hebei Hanlin’s shareholding restructuring before the end of February 2015.

4. Hebei Hanlin, after shareholding restructuring, can authorize No.4 Pharma to produce the products and manage the operation once the products or technology developments successfully achieve commercialization which can also transfer the relevant titles to No.4 Pharma or a third party. No.4 Pharma shall have the first priority to acquire the relevant titles in case the offered terms compared to the others are the same.

The current major product types of Hebei Hanlin including (1) Primary Antibody (targets an antigen directly and can be very useful for the detection of biomarkers for diseases such as cancer, diabetes etc.) 、 (2) Secondary Antibody (aids in the detection by coloring or lighting by binding to a primary antibody) 、 (3) Serum Free Medium for Stem Cell and (4) spot TB test kits.

Shareholders of the Company and the potential investors are advised to exercise caution when dealing in the Shares.

By Order of the Board
Chan Ka Kit
Company Secretary

Hong Kong, 21 January 2015

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.